The Middle East and Africa Continuous Glucose Monitoring Market size is estimated at USD 261.03 million in 2024, and is expected to reach USD 477.33 million by 2029, growing at a CAGR of 12.83% during the forecast period (2024-2029).
During the COVID-19 pandemic patients with diabetes, infected experienced additional stress and increased secretion of hyperglycemic hormones. To avoid aggravation, a patient's blood glucose monitoring had to be considered during the COVID-19 patient's hospitalization which highlighted the importance of continuous glucose monitoring devices. Pandemic emergency created a surge in remote care from both patients and providers and removed many long-standing regulatory barriers. Thus, the COVID-19 outbreak increased the continuous glucose monitoring device market's growth.
73 million adults (20-79) are living with diabetes in the IDF MENA Region in 2021. This figure is estimated to increase to 95 million by 2030. 48 million adults in the IDF MENA Region are living with Impaired Glucose Tolerance, which places them at increased risk of developing type 2 diabetes. Diabetes is responsible for 796,000 deaths in the IDF MENA Region in 2021. USD 33 billion was spent on healthcare for people with diabetes in 2021.
The Middle East and African region had witnessed an alarming increase in the prevalence of diabetes, in recent years, the rate of diabetes is at an all-time high, mainly due to lifestyle changes. Diabetes is associated with many health complications. Patients with diabetes require many corrections throughout the day to maintain nominal blood glucose levels, such as administering additional insulin or ingesting additional carbohydrates by monitoring their blood glucose levels. Diabetes poses an emerging healthcare burden across the region The Type 1 diabetes population completely depends on insulin therapy. Therefore, they constantly need to monitor their blood glucose levels. Some Type 2 diabetes patients also depend on insulin therapy and 90% of the diabetic population is type 2, most of them use Continuous glucose monitoring devices to monitor their insulin levels.
Owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.
To use a CGM, a small sensor is inserted into the abdomen or arm with a tiny plastic tube known as a cannula penetrating the top layer of skin. An adhesive patch holds the sensor in place, allowing it to take glucose readings in interstitial fluid throughout the day and night. Generally, the sensors must be replaced every 7 to 14 days. A small, reusable transmitter connected to the sensor allows the system to send real-time readings wirelessly to a monitor device that displays blood glucose data. Some systems come with a dedicated monitor, and some display the information via a smartphone app.
CGM sensors have proven to be effective for patients with frequent hypoglycemic events, sensor-augmented pumps, and gestational diabetes treated with either continuous subcutaneous insulin infusion or a multiple daily injection insulin regimen. Researchers are trying to find and develop alternatives to electrochemical-based glucose sensors and create more affordable, minimally invasive, and user-friendly CGM sensors. Optical measurement is a promising platform for glucose sensing. Some technologies have been reported to have high potential for continuous glucose sensing, including spectroscopy, fluorescence, holographic technology, etc. Eversense, a CGM sensor based on fluorescence sensing developed by Senseonics Company, presents a much longer lifespan in comparison with electrochemical sensors.
73 million adults were living with diabetes in the IDF MENA Region in 2021. This figure is estimated to increase to 95 million by 2030. 48 million adults in the IDF MENA region live with impaired glucose tolerance, which places them at increased risk of developing type-2 diabetes. Governments in the Middle East have identified the threat of diabetes and started to respond with various policies, initiatives, and programs. Six out of 15 countries in this region still do not have a national operational action policy for diabetes. Many countries still do not have a national strategy to reduce overweight, obesity, and physical inactivity, which are important risk factors for diabetes. Most counties have fully implemented national diabetes treatment guidelines. However, constant measures are being taken to minimize diabetic complications; therefore, owing to the aforesaid factors, the growth of the studied market is anticipated in the Middle East and African region.
More than one in ten people in Saudi Arabia were living with diabetes, and the prevalence of the disease was expected to almost double by 2045, according to the report by the IDF 2021. The IDF report 2021 mentioned that 4.27 million people in Saudi Arabia, which has a population of about 34.8 million, had diabetes, while a further 1.86 million people have the disease but are yet to be diagnosed.
It is imperative that CGM devices be used alongside insulin pumps. As the trends show a higher number of diabetic patients using insulin pumps for diabetes management, it can be predicted that the number of units of CGM devices sold will also follow. Type-1 patients require continuous monitoring to keep a close watch on their glucose levels, which is likely to generate demand in the coming years. Due to the adaptability of new technology and the high prevalence of diabetes in the population, Saudi Arabia dominates the market, among other countries.
In July 2022, the Saudi Government announced that Saudi Arabia saw growing demand for quality healthcare services spurred by changes, including an increasing and aging population and a growing prevalence of lifestyle diseases such as diabetes and obesity. The government and private sector are both involved in working on healthcare entities, certifications, and regulations. The government is taking steps to have 100 percent of Saudi citizens covered by insurance and is working towards ensuring affordability, access, and quality digital healthcare and primary care with cost-effectiveness.
Therefore, owing to the aforesaid factors, the growth of the studied market is anticipated in the Middle East and Africa region.
This product will be delivered within 2 business days.
During the COVID-19 pandemic patients with diabetes, infected experienced additional stress and increased secretion of hyperglycemic hormones. To avoid aggravation, a patient's blood glucose monitoring had to be considered during the COVID-19 patient's hospitalization which highlighted the importance of continuous glucose monitoring devices. Pandemic emergency created a surge in remote care from both patients and providers and removed many long-standing regulatory barriers. Thus, the COVID-19 outbreak increased the continuous glucose monitoring device market's growth.
73 million adults (20-79) are living with diabetes in the IDF MENA Region in 2021. This figure is estimated to increase to 95 million by 2030. 48 million adults in the IDF MENA Region are living with Impaired Glucose Tolerance, which places them at increased risk of developing type 2 diabetes. Diabetes is responsible for 796,000 deaths in the IDF MENA Region in 2021. USD 33 billion was spent on healthcare for people with diabetes in 2021.
The Middle East and African region had witnessed an alarming increase in the prevalence of diabetes, in recent years, the rate of diabetes is at an all-time high, mainly due to lifestyle changes. Diabetes is associated with many health complications. Patients with diabetes require many corrections throughout the day to maintain nominal blood glucose levels, such as administering additional insulin or ingesting additional carbohydrates by monitoring their blood glucose levels. Diabetes poses an emerging healthcare burden across the region The Type 1 diabetes population completely depends on insulin therapy. Therefore, they constantly need to monitor their blood glucose levels. Some Type 2 diabetes patients also depend on insulin therapy and 90% of the diabetic population is type 2, most of them use Continuous glucose monitoring devices to monitor their insulin levels.
Owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.
Middle East and Africa Continuous Glucose Monitoring Market Trends
The sensors segment holds the highest market share in the Middle East and African Continuous Glucose Monitoring Market in the current year
Sensors hold the highest market share in the current year and are expected to register a CAGR of about 11.6% over the forecast period.To use a CGM, a small sensor is inserted into the abdomen or arm with a tiny plastic tube known as a cannula penetrating the top layer of skin. An adhesive patch holds the sensor in place, allowing it to take glucose readings in interstitial fluid throughout the day and night. Generally, the sensors must be replaced every 7 to 14 days. A small, reusable transmitter connected to the sensor allows the system to send real-time readings wirelessly to a monitor device that displays blood glucose data. Some systems come with a dedicated monitor, and some display the information via a smartphone app.
CGM sensors have proven to be effective for patients with frequent hypoglycemic events, sensor-augmented pumps, and gestational diabetes treated with either continuous subcutaneous insulin infusion or a multiple daily injection insulin regimen. Researchers are trying to find and develop alternatives to electrochemical-based glucose sensors and create more affordable, minimally invasive, and user-friendly CGM sensors. Optical measurement is a promising platform for glucose sensing. Some technologies have been reported to have high potential for continuous glucose sensing, including spectroscopy, fluorescence, holographic technology, etc. Eversense, a CGM sensor based on fluorescence sensing developed by Senseonics Company, presents a much longer lifespan in comparison with electrochemical sensors.
73 million adults were living with diabetes in the IDF MENA Region in 2021. This figure is estimated to increase to 95 million by 2030. 48 million adults in the IDF MENA region live with impaired glucose tolerance, which places them at increased risk of developing type-2 diabetes. Governments in the Middle East have identified the threat of diabetes and started to respond with various policies, initiatives, and programs. Six out of 15 countries in this region still do not have a national operational action policy for diabetes. Many countries still do not have a national strategy to reduce overweight, obesity, and physical inactivity, which are important risk factors for diabetes. Most counties have fully implemented national diabetes treatment guidelines. However, constant measures are being taken to minimize diabetic complications; therefore, owing to the aforesaid factors, the growth of the studied market is anticipated in the Middle East and African region.
Saudi Arabia is expected to dominate the Middle East and Africa Continuous Glucose Monitoring Market over the forecast period
Saudi Arabia holds the largest share in the continuous glucose monitoring market in the Middle East and African region and is expected to register a CAGR of about 11.6% over the forecast period.More than one in ten people in Saudi Arabia were living with diabetes, and the prevalence of the disease was expected to almost double by 2045, according to the report by the IDF 2021. The IDF report 2021 mentioned that 4.27 million people in Saudi Arabia, which has a population of about 34.8 million, had diabetes, while a further 1.86 million people have the disease but are yet to be diagnosed.
It is imperative that CGM devices be used alongside insulin pumps. As the trends show a higher number of diabetic patients using insulin pumps for diabetes management, it can be predicted that the number of units of CGM devices sold will also follow. Type-1 patients require continuous monitoring to keep a close watch on their glucose levels, which is likely to generate demand in the coming years. Due to the adaptability of new technology and the high prevalence of diabetes in the population, Saudi Arabia dominates the market, among other countries.
In July 2022, the Saudi Government announced that Saudi Arabia saw growing demand for quality healthcare services spurred by changes, including an increasing and aging population and a growing prevalence of lifestyle diseases such as diabetes and obesity. The government and private sector are both involved in working on healthcare entities, certifications, and regulations. The government is taking steps to have 100 percent of Saudi citizens covered by insurance and is working towards ensuring affordability, access, and quality digital healthcare and primary care with cost-effectiveness.
Therefore, owing to the aforesaid factors, the growth of the studied market is anticipated in the Middle East and Africa region.
Middle East and Africa Continuous Glucose Monitoring Industry Overview
The Middle East and African continuous glucose monitoring market is consolidated, with a few major manufacturers like Dexcom, Medtronic, etc. present in the market.Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION
6 MARKET INDICATORS
7 COMPETITIVE LANDSCAPE
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Diabetes Care
- Dexcom
- Medtronics
- Senseonics
- GlySens
Methodology
LOADING...
